These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 19245910)

  • 1. A specific vascular endothelial growth factor receptor tyrosine kinase inhibitor enhances the antiproliferative effect of trastuzumab in human epidermal growth factor receptor 2 overexpressing breast cancer cell lines.
    Kim EM; Lobocki C; Dubay L; Mittal VK
    Am J Surg; 2009 Mar; 197(3):331-6. PubMed ID: 19245910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
    Cuello M; Ettenberg SA; Clark AS; Keane MM; Posner RH; Nau MM; Dennis PA; Lipkowitz S
    Cancer Res; 2001 Jun; 61(12):4892-900. PubMed ID: 11406568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
    Seoane S; Montero JC; Ocaña A; Pandiella A
    J Natl Cancer Inst; 2010 Sep; 102(18):1432-46. PubMed ID: 20811002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
    Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
    Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additive effects of trastuzumab and genistein on human breast cancer cells.
    Lattrich C; Lubig J; Springwald A; Goerse R; Ortmann O; Treeck O
    Anticancer Drugs; 2011 Mar; 22(3):253-61. PubMed ID: 21160418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.
    Kim WE; Serrero G
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4192-9. PubMed ID: 16857791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis.
    Budman DR; Soong R; Calabro A; Tai J; Diasio R
    Anticancer Drugs; 2006 Sep; 17(8):921-8. PubMed ID: 16940802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetuximab enhances the anti-proliferative effect of trastuzumab in ERBB2 over-expressing breast cancer cells--preliminary study.
    Uberall I; Krízová K; Steigerová J
    Klin Onkol; 2011; 24(5):356-60. PubMed ID: 22070017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer.
    Lesniak D; Xu Y; Deschenes J; Lai R; Thoms J; Murray D; Gosh S; Mackey JR; Sabri S; Abdulkarim B
    Cancer Res; 2009 Nov; 69(22):8620-8. PubMed ID: 19887601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.
    Chen W; Wei F; Xu J; Wang Y; Chen L; Wang J; Guan X
    Int J Mol Med; 2011 Dec; 28(6):985-91. PubMed ID: 21887460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
    Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual targeting of EGFR and HER-2 in colon cancer cell lines.
    Giannopoulou E; Antonacopoulou A; Floratou K; Papavassiliou AG; Kalofonos HP
    Cancer Chemother Pharmacol; 2009 May; 63(6):973-81. PubMed ID: 18751705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab.
    Cavalloni G; Sarotto I; Pignochino Y; Gammaitoni L; Migliardi G; Sgro L; Piacibello W; Risio M; Aglietta M; Leone F
    Anticancer Drugs; 2008 Aug; 19(7):689-96. PubMed ID: 18594210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
    Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
    Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines.
    Gong SJ; Jin CJ; Rha SY; Chung HC
    Cancer Lett; 2004 Oct; 214(2):215-24. PubMed ID: 15363548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.